Anjan K Pradhan Selected Research

Syntenins

1/2021	Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β.
1/2020	MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein.
1/2020	MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis.
12/2019	MDA-9/Syntenin (SDCBP) Is a Critical Regulator of Chemoresistance, Survival and Stemness in Prostate Cancer Stem Cells.
11/2019	Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor.
10/2019	Regulation of neuroblastoma migration, invasion, and in vivo metastasis by genetic and pharmacological manipulation of MDA-9/Syntenin.
1/2018	Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin.
1/2018	The MDA-9/Syntenin/IGF1R/STAT3 Axis Directs Prostate Cancer Invasion.
1/2018	MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells.
8/2016	Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anjan K Pradhan Research Topics

Disease

24	Neoplasms (Cancer) 03/2022 - 01/2016
14	Melanoma (Melanoma, Malignant) 01/2022 - 01/2016
10	Neoplasm Metastasis (Metastasis) 12/2021 - 07/2016
4	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2018
4	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 08/2016
3	Neuroblastoma 01/2020 - 01/2016
3	Glioma (Gliomas) 01/2018 - 08/2016
2	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2017
2	Inflammation (Inflammations) 01/2018 - 07/2016
1	Experimental Melanoma 01/2022
1	Liver Neoplasms (Liver Cancer) 01/2020
1	Infections 01/2016

Drug/Important Bio-Agent (IBA)

11	SynteninsIBA 01/2021 - 07/2016
6	Proteins (Proteins, Gene)FDA Link 12/2021 - 08/2016
5	CytokinesIBA 01/2022 - 01/2018
5	SyndecansIBA 01/2021 - 01/2018
5	Carrier Proteins (Binding Protein)IBA 01/2021 - 01/2018
3	Interleukin-10 (Interleukin 10)IBA 12/2021 - 01/2018
3	InterleukinsIBA 12/2021 - 01/2016
3	MicroRNAs (MicroRNA)IBA 01/2019 - 01/2017
2	interleukin-24 (ST16)IBA 01/2022 - 01/2018
2	Biological ProductsIBA 12/2021 - 11/2020
2	mezereinIBA 11/2020 - 01/2018
2	Interferon-betaIBA 11/2020 - 01/2018
2	Pharmaceutical PreparationsIBA 11/2019 - 01/2017
2	Beclin-1IBA 01/2018 - 01/2017
2	Interleukin-6 (Interleukin 6)IBA 01/2018 - 01/2017
2	Caspase 3 (Caspase-3)IBA 01/2017 - 01/2016
1	GATA2 Transcription FactorIBA 03/2022
1	Transcription Factors (Transcription Factor)IBA 03/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2021
1	AntigensIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Interleukin-8 (Interleukin 8)IBA 01/2018
1	Recombinant ProteinsIBA 01/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2017
1	somatostatin receptor 2IBA 01/2017
1	LigandsIBA 01/2017
1	Liposomes (Liposome)IBA 01/2017
1	Apoptosis Regulatory ProteinsIBA 01/2017
1	diacereinIBA 01/2017
1	Interleukin-17 (Interleukin 17)IBA 07/2016
1	AD 5IBA 01/2016
1	CaspasesIBA 01/2016

Therapy/Procedure

16	Therapeutics 01/2022 - 01/2016
1	Precision Medicine 02/2021
1	Immunotherapy 01/2021
1	Drug Therapy (Chemotherapy) 01/2021